Details of Research Outputs

TitleA high-throughput drug screening strategy against coronaviruses
Author (Name in English or Pinyin)
Liu, J.1; Li, K.1; Cheng, L.2; Shao, J.1; Yang, S.1; Zhang, W.3; Zhou, G.4; de Vries, A.A.F.5; Yu, Z.6
Date Issued2021-02-01
Source PublicationInternational Journal of Infectious Diseases Open Access
ISSN12019712
DOI10.1016/j.ijid.2020.12.033
Education discipline科技类
Published range国外学术期刊
Volume Issue Pages卷: 103 页: 300-304
References
[1] Almazán, F., Sola, I., Zuñiga, S., Marquez-Jurado, S., Morales, L., Becares, M., et al. Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res 189 (2014), 262–270.
[2] Bárcena, M., Oostergetel, G.T., Bartelink, W., Faas, F.G., Verkleij, A., Rottier, P.J., et al. Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion. Proc Natl Acad Sci U S A 106:2 (2009), 582–587.
[3] Bill Gallaher, Remarkable Age Distribution of OC43 vs. SARS-CoV-2 in China. [Internet]. Available from:, 2020 https://virological.org/t/remarkable-age-distribution-of-oc43-vs-sars-cov-2-in-china/399.
[4] Burki, T.K., Coronavirus in China. Lancet Respir Med, 8(3), 2020, 238.
[5] Chen, L., Liu, W., Zhang, Q., Xu, K., Ye, G., Wu, W., et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect 9:1 (2020), 313–319.
[6] Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:10223 (2020), 507–513.
[7] Dragovich, P.S., Prins, T.J., Zhou, R., Johnson, T.O., Hua, Y., Luu, H.T., et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem 46:21 (2003), 4572–4585.
[8] Fung, T.S., Liu, D.X., Human coronavirus: host-pathogen interaction. Annu Rev Microbiol 73 (2019), 529–557.
[9] Gao, G.F., From “A” IV to “Z” IKV: attacks from emerging and re-emerging pathogens. Cell 172:6 (2018), 1157–1159.
[10] Gralinski, L.E., Menachery, V.D., Return of the coronavirus: 2019-nCoV. Viruses, 12(2), 2020.
[11] Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:18 (2020), 1708–1720.
[12] Hegyi, A., Ziebuhr, J., Conservation of substrate specificities among coronavirus main proteases. J Gen Virol 83:Pt 3 (2002), 595–599.
[13] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:10223 (2020), 497–506.
[14] Hung, M., Gibbs, C.S., Tsiang, M., Biochemical characterization of rhinovirus RNA-dependent RNA polymerase. Antivir Res 56:2 (2002), 99–114.
[15] ICTV, Virus Taxonomy: the Classification and Nomenclature of Viruses the 9th Report of the ICTV. [Internet]. 2011. Available from:, 2011 https://talk.ictvonline.org/ictv-reports/ictv_9th_report/.
[16] Kindler, E., Gil-Cruz, C., Spanier, J., Li, Y., Wilhelm, J., Rabouw, H.H., et al. Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathog, 13(2), 2017, e1006195.
[17] Lehmann, K.C., Gulyaeva, A., Zevenhoven-Dobbe, J.C., Janssen, G.M., Ruben, M., Overkleeft, H.S., et al. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res 43:17 (2015), 8416–8434.
[18] Li, G., De Clercq, E., Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:3 (2020), 149–150.
[19] Li, Y., Liu, X., Guo, L., Li, J., Zhong, D., Zhang, Y., et al. Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis. Syst Rev, 9(1), 2020, 75.
[20] Novella, I.S., Contributions of vesicular stomatitis virus to the understanding of RNA virus evolution. Curr Opin Microbiol 6:4 (2003), 399–405.
[21] Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Müller, M.A., Dijkman, R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:7440 (2013), 251–254.
[22] Ren, J.L., Zhang, A.H., Wang, X.J., Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res, 155, 2020, 104743.
[23] Smith, E.C., Case, J.B., Blanc, H., Isakov, O., Shomron, N., Vignuzzi, M., et al. Mutations in coronavirus non-structural protein 10 decrease virus replication fidelity. J Virol 89:12 (2015), 6418–6426.
[24] St-Jean, J.R., Jacomy, H., Desforges, M., Vabret, A., Freymuth, F., Talbot, P.J., Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J Virol 78:16 (2004), 8824–8834.
[25] Wang, Y., Sun, Y., Wu, A., Xu, S., Pan, R., Zeng, C., et al. Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis. J Virol 89:16 (2015), 8416–8427.
[26] WHO, WHO Director-General's Remarks at the Media Briefing on 2019-nCoV on Feb 11, 2020. [Internet]. Available from:, 2020 https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
[27] Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27:3 (2020), 325–328.
[28] Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., et al. A new coronavirus associated with human respiratory disease in China. Nature 579:7798 (2020), 265–269.
[29] Wu, H., Wang, J., Yang, Y., Li, T., Cao, Y., Qu, Y., et al. Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology. Acta Pharmaceutica Sinica 55:3 (2020), 374–383.
[30] Yang, Y., Islam, M.S., Wang, J., Li, Y., Chen, X., Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 16:10 (2020), 1708–1717.
[31] Zhang, K., Is traditional Chinese medicine useful in the treatment of COVID-19?. Am J Emerg Med, 38(10), 2020, 2238.
[32] Zhou, J.F., Hua, X.G., Cui, L., Zhu, J.G., Miao, D.N., Zou, Y., et al. Effective inhibition of porcine transmissible gastroenteritis virus replication in ST cells by shRNAs targeting RNA-dependent RNA polymerase gene. Antivir Res 74:1 (2007), 36–42.
[33] Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv(January), 2020, 914952 [Internet]. Available from: https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf.
[34] Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:7798 (2020), 270–273.
[35] Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., Yuen, K.Y., Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 15:5 (2016), 327–347.
Citation statistics
Cited Times:9[WOS]   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
Identifierhttps://irepository.cuhk.edu.cn/handle/3EPUXD0A/2174
CollectionSchool of Science and Engineering
The Third Affiliated Hospital of The Chinese University of Hong Kong, Shenzhen
Affiliation
1.Central Laboratory, Longgang Distract People's Hospital of Shenzhen & The Third Affiliated Hospital (Provisional) of The Chinese University of Hong Kong, Shenzhen, China
2.Shenzhen Key Laboratory of Infection and Immunity, Guangdong Key Laboratory of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China
3.Department of Emergency, People's Hospital of Leling, Dezhou, Shandong, China
4.Department of Medical Cell Biology and Genetics, Guangdong Key Laboratory of Genome Stability & Disease Prevention, Shenzhen Key Laboratory for Anti-ageing and Regenerative Medicine, Health Science Center, Shenzhen University, Shenzhen, China
5.Laboratory of Experimental Cardiology, Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands
6.Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250100, China
Recommended Citation
GB/T 7714
Liu, J.,Li, K.,Cheng, L.et al. A high-throughput drug screening strategy against coronaviruses[J]. International Journal of Infectious Diseases Open Access,2021.
APA Liu, J., Li, K., Cheng, L., Shao, J., Yang, S., .. & Yu, Z. (2021). A high-throughput drug screening strategy against coronaviruses. International Journal of Infectious Diseases Open Access.
MLA Liu, J.,et al."A high-throughput drug screening strategy against coronaviruses".International Journal of Infectious Diseases Open Access (2021).
Files in This Item:
File Name/Size DocType File Type Version Access License
A high-throughput dr(592KB)Journal article--Published draftRestricted AccessCC BY-NC-SA
Related Services
Usage statistics
Google Scholar
Similar articles in Google Scholar
[Liu, J.]'s Articles
[Li, K.]'s Articles
[Cheng, L.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Liu, J.]'s Articles
[Li, K.]'s Articles
[Cheng, L.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Liu, J.]'s Articles
[Li, K.]'s Articles
[Cheng, L.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.